US 12,077,584 B2
Methods of treating HLA-E-expressing cancers by administering antibodies which bind human natural killer cell inhibitory receptor group 2A (NKG2A)
Natalie Bezman, Foster City, CA (US); Alan J. Korman, Piedmont, CA (US); Shrikant Deshpande, Fremont, CA (US); Amy D. Jhatakia, Fremont, CA (US); Richard Y. Huang, Bridgewater, NJ (US); Guodong Chen, East Brunswick, NJ (US); Ginger C. Rakestraw, Somerville, MA (US); Karla Ann Henning, Milpitas, CA (US); Vangipuram S. Rangan, Pleasant Hill, CA (US); Christine Bee, San Francisco, CA (US); and Xiang Shao, Los Altos, CA (US)
Assigned to Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed by BRISTOL-MYERS SQUIBB COMPANY, Princeton, NJ (US)
Filed on Feb. 11, 2022, as Appl. No. 17/670,398.
Application 17/670,398 is a division of application No. 16/683,927, filed on Nov. 14, 2019, granted, now 11,274,150.
Claims priority of provisional application 62/927,211, filed on Oct. 29, 2019.
Claims priority of provisional application 62/768,471, filed on Nov. 16, 2018.
Prior Publication US 2022/0204618 A1, Jun. 30, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 1/22 (2006.01); C12N 5/071 (2010.01); C12N 15/85 (2006.01); C12P 21/00 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 39/3955 (2013.01); A61K 47/6849 (2017.08); A61P 35/00 (2018.01); C07K 1/22 (2013.01); C12N 5/0682 (2013.01); C12N 15/85 (2013.01); C12P 21/005 (2013.01); G01N 33/68 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C12N 2510/02 (2013.01); C12N 2800/107 (2013.01)] 76 Claims
 
1. A method of treating a cancer expressing HLA-E in a subject in need thereof comprising administering to the subject an isolated antibody or antigen-binding fragment thereof that binds human NKG2A wherein said antibody comprises an HCDR1, an HCDR2 and an HCDR3 of a VH of the amino acid sequence of SEQ ID NO:8 and a LCDR1, an LCDR2 and an LCDR3 of a VL of the amino acid sequence of SEQ ID NO:9.